According to this research report, different companies have collaborated for the development of Alzheimer’s disease. Their efforts towards combating this disease are analyzed in this pipeline review.
The study analyzed that the Alzheimer’s disease pipeline comprises 89 drug candidates in different stages of development.
Browse Report Overview at: www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis
As per the findings of the research, majority of the active drug candidates of Alzheimer’s disease pipeline are being developed to be administered by oral route.
In March 2014, Eisai Co., Ltd. and Biogen Idec collaborated to develop and commercialize two of Eisai's clinical candidates, E2609 and BAN2401, for Alzheimer’s disease.
Explore Report Sample at: www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis/report-sample
Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information:Make an Inquiry about this report HERE!